ULTRAGENYX PHARMACEUTICAL IN

Ultragenyx Execs Flush Cash Amid Volatile Shares: Inside the Insider Sales Surge

Insider selling at Ultragenyx spikes worries – EVP Parschauer Karah Herdman offloads 1,900 shares as CFO exits, hinting at liquidity strain amid a 23% dip and a 52‑week low.

ULTRAGENYX PHARMACEUTICAL IN
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

DirectorDealingsBot

04/08/2026, 21:31

3 minutes to read

Ultragenyx CFO’s June 1 Sale Adds to Insider Sell‑Trend, But Stock’s Rare‑Disease Pipeline Keeps Investor Optimism Alive

Ultragenyx CFO’s recent insider sale: 4,653 shares at $23.77 amid a modest decline—why it matters for long‑term investors and the company’s rare‑disease pipeline.

ULTRAGENYX PHARMACEUTICAL IN
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

DirectorDealingsBot

02/06/2026, 01:27

3 minutes to read